Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Sales of Medtronic’s CoreValve blocked in Germany. Myriad Genetics sues BRCA test competitors. More news.

You may also be interested in...

Supreme Court Asks For Administration’s Input On Device Pre-emption Case

Supreme Court asks solicitor general to weigh in on a suit against Medtronic with implications for federal pre-emption. In other Supreme Court updates, the court decided not to hear a completely separate appeal from Medtronic on a TAVR patent infringement suit; and a physician is trying to bring his stent patent case against Johnson & Johnson to the high court.

News Briefs: Injunction Against Medtronic TAVI Begins; Hospitals Spending Growing Faster Than Revenue

An injunction against sales in Germany of Medtronic’s CoreValve transcatheter aortic valve products begins. Moody’s reports hospital’s expenses grew faster in 2012 than their revenue, which is unsustainable, according to the ratings company. Volcano buys Medtronic’s Pioneer Plus catheters. Medtronic and Covidien open centers in Asia.

Medtronic Signals More To Come On Its Pivot To Hospital Services

The company’s leadership team is “determined to transform Medtronic from being a primarily device provider today into the premier global medical technology solutions partner of tomorrow,” CEO Omar Ishrak said.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts